Novartis Discusses Ophthalmic Pipeline, $465M Encore Vision Deal in 2016 Annual Report

February 10, 2017: By Joan McKenna

novartis1Novartis has provided details of its ophthalmic pharmaceutical pipeline in its 2016 annual report and related material, released Jan. 25.

The Switzerland-based firm said it closed its acquisition of Encore Vision and Encore’s UNR844 technology for presbyopia on Jan. 20. Novartis paid $375 million up front, plus $90 million in early milestone payments, for a total of $465 million. Some industry analysts report that potential milestone payments could double the total.

A Phase II dose finding study of UNR844 is now in the planning stages, and the company has set a target of 2021 for filing for marketing approval.

UNR844, formerly EV06 ophthalmic solution (lipoic acid choline ester, 1.5%), is described as a prodrug to metabolize dihydrolipoic acid (DHLA). It is designed to improve flexibility in the crystalline lens through twice daily drops for six months, with the effects sustained for six months.

Retinal pipeline

RTH258: Novartis has been developing RTH258 (brolucizumab), an anti-VEGF agent, as a treatment for wet age-related macular degeneration (AMD). The firm said it plans to report the results of two Phase III trials in the first half of 2017 and file a marketing application with the US FDA in 2018. Novartis also will seek approval in the European Union and Japan. It said the single-chain antibody fragment may be longer acting than approved treatments for AMD.

Lucentis: Novartis said it continues to develop Lucentis (ranibizumab), an anti-VEGF agent that was originally approved for wet AMD. The company markets Lucentis outside the US. In 2016, Novartis received EU approval for the drug in visual impairment due to choroidal neovascularization associated with causes other than wet AMD or secondary pathologic myopia.

Lucentis is undergoing Phase II clinical study for retinopathy of prematurity, with an expected completion date of 2018. The company plans for file an application for the added indication in 2018.

Novartis said it is also exploring potential new therapies for glaucoma, dry eye, and other ocular conditions.

It is developing many biosimilars, including a Humira (adalimumab) biosimilar, with a planned filing for approval in 2017. AbbVie’s Humira, a rheumatoid arthritis treatment, is also indicated for uveitis.

Surgical pipeline

On the surgical side under its Alcon eye care division, Novartis plans to file for marketing approval of its Clareon next-generation monofocal IOL in 2017 in Europe and in 2019 in the US. It will seek US approval of its PanOptix trifocal and trifocal toric lenses in 2019. And the firm lists a mid-tier phacoemulsification device as being on track for commercialization in the US and EU in 2018.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023